SMMT | Consolidation Almost Complete | LONGSummit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−6.41 MXN
−4.61 B MXN
0.00 MXN
111.13 M
About Summit Therapeutics Inc.
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.
SMMT | Descending Triangle Pattern - Watch for Breakout & RetestSummit Therapeutics Inc. (SMMT) is consolidating within a descending triangle pattern , nearing a critical breakout zone. With price action hovering around the $18.57 support level, a breakout and retest of the resistance trendline could trigger a significant upside move.
Key Setup
Triangle Ran
Summit Therapeutics Inc.: Navigating the Bearish Phase After ATHAfter reaching an all-time high of $33.89, Summit Therapeutics Inc. seems to be entering a bearish phase. This shift raises questions about whether the stock will rebound or continue its downward trend. Historically, many biotech and therapeutics companies often experience pullbacks after substantia
$SMMT Stock Surges on Positive Lung Cancer Drug Trial ResultsShares of Summit Therapeutics (NASDAQ: NASDAQ:SMMT ) surged dramatically, soaring to an all-time high after the biotech firm reported promising results from its Phase 3 trial of ivonescimab, an experimental lung cancer treatment. The news sent the stock up by as much as 75.2% during intraday tradin
SMMT - risky Phase 2 play 03 22/2024Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiot
Uptrend becomes a trend lineThe key influencers of trends are the fundamental factors driving the underlying financial asset and market sentiment.
As an example of fundamental factors, the price development of a share can be a reflection of the company's economic strength.
Accordingly, a price increase may be due to the com
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of SMMT is 398.00 MXN — it has decreased by −6.42% in the past 24 hours. Watch SUMMIT THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange SUMMIT THERAPEUTICS INC stocks are traded under the ticker SMMT.
SMMT stock has fallen by −3.99% compared to the previous week, the month change is a −3.70% fall, over the last year SUMMIT THERAPEUTICS INC has showed a 54.88% increase.
We've gathered analysts' opinions on SUMMIT THERAPEUTICS INC future price: according to them, SMMT price has a max estimate of 894.85 MXN and a min estimate of 610.13 MXN. Watch SMMT chart and read a more detailed SUMMIT THERAPEUTICS INC stock forecast: see what analysts think of SUMMIT THERAPEUTICS INC and suggest that you do with its stocks.
SMMT stock is 6.86% volatile and has beta coefficient of 3.88. Track SUMMIT THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is SUMMIT THERAPEUTICS INC there?
Today SUMMIT THERAPEUTICS INC has the market capitalization of 387.65 B, it has decreased by −0.30% over the last week.
Yes, you can track SUMMIT THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
SUMMIT THERAPEUTICS INC is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
SMMT earnings for the last quarter are −1.67 MXN per share, whereas the estimation was −1.71 MXN resulting in a 2.21% surprise. The estimated earnings for the next quarter are −1.91 MXN per share. See more details about SUMMIT THERAPEUTICS INC earnings.
SUMMIT THERAPEUTICS INC revenue for the last quarter amounts to 0.00 MXN, matching the estimated figure, and no changes in revenue are expected for the next quarter.
SMMT net income for the last quarter is −1.28 B MXN, while the quarter before that showed −1.11 B MXN of net income which accounts for −15.12% change. Track more SUMMIT THERAPEUTICS INC financial stats to get the full picture.
No, SMMT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 159 employees. See our rating of the largest employees — is SUMMIT THERAPEUTICS INC on this list?
Like other stocks, SMMT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SUMMIT THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.